Sign in
IGMS Stock Price, Chart, Stats & News
IGM Biosciences, Inc.
Save
77.50M
Market cap
–
Current P/E
–
Forward P/E
IGMS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 98.07% |
Operating margin | -19.20% |
Pretax margin | -36.80% |
Net margin | -36.80% |
Effective tax rate | – |
ROA | -49.90% |
ROE | -93.35% |
D/E | – |
Interest coverage ratio | – |
IGMS valuation
P/E | – |
P/S | 0.53x |
P/B | 0.77x |
P/CF | -0.50x |
P/FCF | -0.49x |
P/OCF | -0.50x |
PEG | -0.02x |
EV multiple | -3.46x |
About
IGM Biosciences, Inc. operates as a biotechnology firm dedicated to advancing Immunoglobulin M (IgM) antibodies. These novel therapeutic agents are being developed for a broad spectrum of conditions, including various cancers, infectious ailments, and autoimmune and inflammatory disorders. The company's most advanced experimental treatment is IGM-2323, a bispecific IgM antibody.
Similar securities
Based on sector and market capitalization
Report issue